Published in Expert Opin Pharmacother on April 05, 2015
Improved detection of deeply invasive candidiasis with DNA aptamers specific binding to (1→3)-β-D-glucans from Candida albicans. Eur J Clin Microbiol Infect Dis (2016) 0.79
Prevention and treatment of neonatal nosocomial infections. Matern Health Neonatol Perinatol (2017) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics (2002) 9.87
Amphotericin B: 30 years of clinical experience. Rev Infect Dis (1990) 5.82
A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med (2007) 4.72
Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med (2001) 4.27
Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics (2006) 3.78
Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J (2000) 3.13
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother (2002) 2.68
Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr (1988) 2.62
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 2.50
Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics (2008) 2.45
Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics (2003) 2.38
Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics (2001) 2.35
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol (2005) 2.32
Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA (2014) 2.30
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother (2008) 2.11
The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics (2006) 2.10
Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis (2000) 2.09
Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J (2004) 2.08
Therapy for fungal diseases: opportunities and priorities. Trends Microbiol (2010) 1.95
Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother (2000) 1.93
Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics (2006) 1.91
Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis (2012) 1.91
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol (2006) 1.88
Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J Infect Dis (1975) 1.88
Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics (2010) 1.86
Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics (2003) 1.86
Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics (2005) 1.74
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2002) 1.72
Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis (1992) 1.71
Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother (2008) 1.68
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother (1998) 1.60
Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother (2005) 1.57
Introduction to antifungal drugs. Clin Infect Dis (2000) 1.56
In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother (2007) 1.55
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol (2003) 1.54
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol (2008) 1.52
Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother (2001) 1.45
Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol (2003) 1.42
Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol (2005) 1.37
Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr (2005) 1.36
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol (2008) 1.36
Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J (2000) 1.35
Renal candidiasis in neonates with candiduria. Pediatr Infect Dis J (1999) 1.33
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother (2008) 1.31
Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr (2005) 1.31
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother (2007) 1.29
Candida parapsilosis infection in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed (2007) 1.28
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother (2007) 1.28
Comparative study of mortality and morbidity in premature infants (birth weight, < 1,250 g) with candidemia or candidal meningitis. Clin Infect Dis (1998) 1.27
Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol (2007) 1.26
Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis (2005) 1.24
Candidal meningitis in neonates: a 10-year review. Clin Infect Dis (2000) 1.24
Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother (2007) 1.23
Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J (2009) 1.20
Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother (2006) 1.19
Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr (2005) 1.19
Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy (1973) 1.19
Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) (2002) 1.16
Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother (2005) 1.13
Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J (2008) 1.13
Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr (1990) 1.11
Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother (2008) 1.11
Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother (2003) 1.10
Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis (2003) 1.10
Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics (2014) 1.08
Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol (2001) 1.08
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother (2008) 1.08
Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother (1989) 1.07
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses (2011) 1.06
Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol (2005) 1.05
Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr Infect Dis J (1995) 1.05
Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr (2007) 1.05
Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother (2006) 1.04
Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J Perinatol (2006) 1.04
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents (2008) 1.03
Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J (1998) 1.01
Candida bloodstream infection in neonates. Semin Perinatol (2003) 0.99
Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev (2007) 0.99
Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol (2005) 0.99
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther (2011) 0.98
Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother (2013) 0.98
Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics (2006) 0.98
Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol (2001) 0.97
Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol (2006) 0.96
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist (2013) 0.95
A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics (2009) 0.94
Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections. Drugs (2015) 0.94
Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother (2002) 0.91
In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis (2000) 0.91
Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother (2011) 0.91
Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J (1999) 0.91
The epidemiology and diagnosis of invasive candidiasis among premature infants. Clin Perinatol (2014) 0.90
Agents for treatment of invasive fungal infections. Otolaryngol Clin North Am (2000) 0.90
Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J (1996) 0.90
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Sports medicine and ethics. Am J Bioeth (2013) 5.51
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2006) 3.70
Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics (2009) 3.05
Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics (2010) 2.48
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Economic return of clinical trials performed under the pediatric exclusivity program. JAMA (2007) 2.28
Early predictors of in-hospital death in infective endocarditis. Circulation (2004) 2.26
Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol (2014) 2.11
The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics (2006) 2.10
Contemporary Fontan operation: association between early outcome and type of cavopulmonary connection. Ann Thorac Surg (2012) 2.04
Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation (2010) 2.01
Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics (2006) 1.98
Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis (2005) 1.92
Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J (2009) 1.90
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit Care Med (2008) 1.69
Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol (2011) 1.64
Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis (2012) 1.63
Use of the complete blood cell count in late-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.63
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. Pediatr Infect Dis J (2008) 1.55
No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J (2015) 1.53
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother (2004) 1.44
Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis (2006) 1.36
Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J (2005) 1.33
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J (2011) 1.30
Value of an inhalational model of invasive aspergillosis. Med Mycol (2004) 1.29
Orbital cellulitis in children. Pediatr Infect Dis J (2006) 1.27
Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother (2012) 1.23
Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr (2013) 1.22
Major infection after pediatric cardiac surgery: a risk estimation model. Ann Thorac Surg (2010) 1.21
Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol (2007) 1.20
Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J (2009) 1.20
Obesity, inflammation, and asthma severity in childhood: data from the National Health and Nutrition Examination Survey 2001-2004. Ann Allergy Asthma Immunol (2009) 1.19
Coagulase-negative staphylococcal infections in the neonatal intensive care unit. Infect Control Hosp Epidemiol (2011) 1.19
AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther (2008) 1.18
Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J (2011) 1.14
Pediatric cardiovascular drug trials, lessons learned. J Cardiovasc Pharmacol (2011) 1.13
Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J (2012) 1.09
Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J (2009) 1.09
Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics (2014) 1.08
In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos (2010) 1.08
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother (2004) 1.08
A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect (2004) 1.08
Use of the complete blood cell count in early-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.07
Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother (2010) 1.06
Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J (2013) 1.06
Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J (2007) 1.05
A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. AIDS (2003) 1.05
Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics (2008) 1.05
Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit (2012) 1.04
Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia. J Lab Clin Med (2004) 1.03
Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr (2012) 1.02
Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J (2013) 1.02
Meningitis in preterm neonates: importance of cerebrospinal fluid parameters. Am J Perinatol (2008) 1.01
Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother (2014) 1.01
Criteria supporting the study of drugs in the newborn. Clin Ther (2006) 1.00
Pediatric residents' clinical diagnostic accuracy of otitis media. Pediatrics (2002) 1.00
Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther (2006) 0.99
Center variation in patient age and weight at Fontan operation and impact on postoperative outcomes. Ann Thorac Surg (2011) 0.98
In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos (2010) 0.98
Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J (2007) 0.97
Nosocomial infection in the NICU: a medical complication or unavoidable problem? J Perinatol (2004) 0.96
Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. Pediatr Infect Dis J (2009) 0.95
Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos (2008) 0.95
Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control (2010) 0.95
Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J (2012) 0.95
Prevention and treatment of nosocomial sepsis in the NICU. J Perinatol (2004) 0.93
Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos (2011) 0.93
Effect of sex and race on outcome in patients undergoing congenital heart surgery: an analysis of the society of thoracic surgeons congenital heart surgery database. Ann Thorac Surg (2012) 0.93
Neonatal candidiasis. Infect Dis Clin North Am (2005) 0.91
The economic returns of pediatric clinical trials of antihypertensive drugs. Am Heart J (2008) 0.91
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J (2012) 0.90
Effect of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit on total hospital cost. Infect Control Hosp Epidemiol (2009) 0.90
Examination of type IV pilus expression and pilus-associated phenotypes in Kingella kingae clinical isolates. Infect Immun (2010) 0.89
Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation (2004) 0.89
Early sepsis does not increase the risk of late sepsis in very low birth weight neonates. J Pediatr (2013) 0.88
Risk factors and prevention of late-onset sepsis in premature infants. Early Hum Dev (2010) 0.88